Details of Disease

Disease Name

Idiopathic hypereosinophilic syndrome

HES; hypereosinophilic syndrome, idiopathic; hypereosinophilic syndrome, idiopathic, resistant to imatinib, isolated cases, somatic mutation

Disease Hierarchy

DISL4MMU: Familial restrictive cardiomyopathy

DISKVWW9: Amyloid cardiomyopathy

DISVK62S: Hypereosinophilic syndrome

DISXAPO9: Idiopathic hypereosinophilic syndrome

Disease Identifiers

MONDO ID

MONDO_0011895

MESH ID

D017681

UMLS CUI

C0206141

OMIM ID

607685

MedGen ID

61525

Orphanet ID

3260

SNOMED CT ID

414450004

General Information of Disease (ID: DISXAPO9)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Imatinib	DM7RJXL	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD52	TTQT5S9	Limited	Biomarker	[2]
CEL	TTTRNQW	Strong	Biomarker	[3]
IL5RA	TTXH9AD	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
RRAGA	OTKISLG4	Limited	Genetic Variation	[5]
RRBP1	OT4ZTPTM	moderate	Biomarker	[5]
NOCT	OTVSYP2D	Strong	Biomarker	[6]
RNASE2	OT8Z4FNE	Strong	Altered Expression	[7]
------------------------------------------------------------------------------------

References

1	Imatinib FDA Label
2	World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.Am J Hematol. 2015 Nov;90(11):1077-89. doi: 10.1002/ajh.24196.
3	World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.Am J Hematol. 2019 Oct;94(10):1149-1167. doi: 10.1002/ajh.25617.
4	Immunological and hematological effects of IL-5(R)-targeted therapy: An overview.Allergy. 2018 Oct;73(10):1979-1988. doi: 10.1111/all.13451. Epub 2018 Oct 8.
5	PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.Cancer Chemother Pharmacol. 2008 Apr;61(4):713-6. doi: 10.1007/s00280-007-0507-7. Epub 2007 Jun 5.
6	Primary eosinophilic disorders: a concise review.Curr Hematol Malig Rep. 2008 Jan;3(1):37-43. doi: 10.1007/s11899-008-0007-9.
7	Familial eosinophilia: a benign disorder?.Blood. 2004 Jun 1;103(11):4050-5. doi: 10.1182/blood-2003-11-3850. Epub 2004 Feb 26.